446 related articles for article (PubMed ID: 19426680)
1. Gene expression profiling of leukemia T-cells resistant to methotrexate and 7-hydroxymethotrexate reveals alterations that preserve intracellular levels of folate and nucleotide biosynthesis.
Fotoohi AK; Assaraf YG; Moshfegh A; Hashemi J; Jansen G; Peters GJ; Larsson C; Albertioni F
Biochem Pharmacol; 2009 Apr; 77(8):1410-7. PubMed ID: 19426680
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis of antifolate resistance.
Assaraf YG
Cancer Metastasis Rev; 2007 Mar; 26(1):153-81. PubMed ID: 17333344
[TBL] [Abstract][Full Text] [Related]
3. Reduced folate carrier mutations are not the mechanism underlying methotrexate resistance in childhood acute lymphoblastic leukemia.
Kaufman Y; Drori S; Cole PD; Kamen BA; Sirota J; Ifergan I; Arush MW; Elhasid R; Sahar D; Kaspers GJ; Jansen G; Matherly LH; Rechavi G; Toren A; Assaraf YG
Cancer; 2004 Feb; 100(4):773-82. PubMed ID: 14770434
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity to 5,10-dideazatetrahydrofolate is fully conserved in a murine leukemia cell line highly resistant to methotrexate due to impaired transport mediated by the reduced folate carrier.
Zhao R; Gao F; Babani S; Goldman ID
Clin Cancer Res; 2000 Aug; 6(8):3304-11. PubMed ID: 10955817
[TBL] [Abstract][Full Text] [Related]
5. 5-amino-4-imidazolecarboxamide riboside potentiates both transport of reduced folates and antifolates by the human reduced folate carrier and their subsequent metabolism.
McGuire JJ; Haile WH; Yeh CC
Cancer Res; 2006 Apr; 66(7):3836-44. PubMed ID: 16585211
[TBL] [Abstract][Full Text] [Related]
6. Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines.
Liani E; Rothem L; Bunni MA; Smith CA; Jansen G; Assaraf YG
Int J Cancer; 2003 Feb; 103(5):587-99. PubMed ID: 12494465
[TBL] [Abstract][Full Text] [Related]
7. The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate.
Zhao R; Babani S; Gao F; Liu L; Goldman ID
Clin Cancer Res; 2000 Sep; 6(9):3687-95. PubMed ID: 10999762
[TBL] [Abstract][Full Text] [Related]
8. The pattern of gene expression and gene dose profiles of 6-Mercaptopurine- and 6-Thioguanine-resistant human leukemia cells.
Karim H; Hashemi J; Larsson C; Moshfegh A; Fotoohi AK; Albertioni F
Biochem Biophys Res Commun; 2011 Jul; 411(1):156-61. PubMed ID: 21723252
[TBL] [Abstract][Full Text] [Related]
9. Folylpolyglutamate synthetase expression in antifolate-sensitive and -resistant human cell lines.
McGuire JJ; Russell CA
Oncol Res; 1998; 10(4):193-200. PubMed ID: 9778690
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms underlying the enhanced sensitivity of thiopurine-resistant T-lymphoblastic cell lines to methyl mercaptopurineriboside.
Fotoohi AK; Wrabel A; Moshfegh A; Peterson C; Albertioni F
Biochem Pharmacol; 2006 Sep; 72(7):816-23. PubMed ID: 16859645
[TBL] [Abstract][Full Text] [Related]
11. Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM.
Pizzorno G; Moroson BA; Cashmore AR; Russello O; Mayer JR; Galivan J; Bunni MA; Priest DG; Beardsley GP
Cancer Res; 1995 Feb; 55(3):566-73. PubMed ID: 7834626
[TBL] [Abstract][Full Text] [Related]
12. Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil.
de Angelis PM; Fjell B; Kravik KL; Haug T; Tunheim SH; Reichelt W; Beigi M; Clausen OP; Galteland E; Stokke T
Int J Oncol; 2004 May; 24(5):1279-88. PubMed ID: 15067352
[TBL] [Abstract][Full Text] [Related]
13. Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.
Verrills NM; Po'uha ST; Liu ML; Liaw TY; Larsen MR; Ivery MT; Marshall GM; Gunning PW; Kavallaris M
J Natl Cancer Inst; 2006 Oct; 98(19):1363-74. PubMed ID: 17018783
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells.
Mauritz R; Bekkenk MW; Rots MG; Pieters R; Mini E; van Zantwijk CH; Veerman AJ; Peters GJ; Jansen G
Clin Cancer Res; 1998 Oct; 4(10):2399-410. PubMed ID: 9796971
[TBL] [Abstract][Full Text] [Related]
15. [Primary study on establishment of namalwa 12/MTX resistant cell strain and its mechanism].
Chen J; Gu LJ; Ying DM; Shen M; Wu HJ
Ai Zheng; 2002 Dec; 21(12):1335-40. PubMed ID: 12520743
[TBL] [Abstract][Full Text] [Related]
16. Impaired CREB-1 phosphorylation in antifolate-resistant cell lines with down-regulation of the reduced folate carrier gene.
Rothem L; Stark M; Assaraf YG
Mol Pharmacol; 2004 Dec; 66(6):1536-43. PubMed ID: 15340044
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms of resistance to antifolates, a review.
Banerjee D; Ercikan-Abali E; Waltham M; Schnieders B; Hochhauser D; Li WW; Fan J; Gorlick R; Goker E; Bertino JR
Acta Biochim Pol; 1995; 42(4):457-64. PubMed ID: 8852336
[TBL] [Abstract][Full Text] [Related]
18. Molecular basis for decreased folylpoly-gamma-glutamate synthetase expression in a methotrexate resistant CCRF-CEM mutant cell line.
Leclerc GJ; York TA; Hsieh-Kinser T; Barredo JC
Leuk Res; 2007 Mar; 31(3):293-9. PubMed ID: 16884772
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of methotrexate resistance in osteosarcoma.
Guo W; Healey JH; Meyers PA; Ladanyi M; Huvos AG; Bertino JR; Gorlick R
Clin Cancer Res; 1999 Mar; 5(3):621-7. PubMed ID: 10100715
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the understanding of the mechanism of membrane transport of folates and antifolates.
Sierra EE; Goldman ID
Semin Oncol; 1999 Apr; 26(2 Suppl 6):11-23. PubMed ID: 10598550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
